Form 4: Avantor Executive Benoit Gourdier Reports Stock and Option Grants

EVP Benoit Gourdier reports acquisition of restricted stock units and stock options in Avantor, Inc.

Summary

• On February 23, 2024, Benoit Gourdier, EVP of Biopharma Production at Avantor, Inc., reported transactions involving Avantor's common stock and stock options.
• Gourdier acquired 25,667 shares of common stock through a grant of restricted stock units.
• These restricted stock units vest in three equal annual installments starting February 23, 2025.
• Additionally, Gourdier acquired 62,753 stock options with an exercise price of $24.35.
• These options also vest in three equal annual installments beginning on February 23, 2025, and expire on February 23, 2034.
• Following these transactions, Gourdier directly owns 42,453 shares of Avantor common stock and 62,753 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, aligning management interests with shareholders. The vesting schedule indicates a long-term commitment.

Positives

• The grant of restricted stock units and stock options to a key executive like Benoit Gourdier aligns his interests with the long-term performance of Avantor.
• The vesting schedule encourages continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements about Avantor's future performance, but the vesting schedule of the stock and options suggests an expectation of continued growth and value creation over the next several years.

Industry Context

This filing is a routine disclosure related to executive compensation. Stock option and restricted stock grants are common practices in the biopharmaceutical industry to incentivize and retain key personnel. These grants align executive interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the life sciences and biopharmaceutical industries.
• Companies like Thermo Fisher Scientific, Danaher, and Merck KGaA also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms, aiming to reward long-term value creation.

Stakeholder Impact

• Shareholders: The grants align executive interests with shareholder value.
• Employees: The grants can serve as a motivation for other employees.
• Management: The grants incentivize management to improve company performance.

Key Dates